TIL Company Profile and Key Details

TIL has shown weak momentum, losing -0.98% over the past week and -62.9% over the past quarter, though year-to-date performance is down -35.64%. Short-term trend indicators are bullishly aligned (SMA20 11.26%, SMA50 3.91%, SMA200 -52.04%). The stock’s 14-day RSI is 57.91 (neutral), while the ATR of 0.58 points to higher daily volatility. The stock remains hovering near 52-week lows, trading -78.99% below its high and over 58.55% above its low. Average 10-day trading volume of 18.97 thousand shares is significantly above the 3-month average of 11.12 thousand, indicating heightened recent market interest.

Instil Bio, Inc. has 6.78 million shares outstanding. The public float is 3.62 million shares, elevated short interest at 4.70% of float. This equals 189.16 thousand shares. The short ratio is 15.58 days. Institutional investors hold 66.88% of the float. Insiders own 6.56%. Crouch Bronson holds 37.98 million shares, Curative Ventures V LLC has 37.98 million shares and Nielsen Jack has 12.49 million shares.

Instil Bio, Inc. generated EPS of -$11.39 over the past year. Five-year average earnings growth is -62.1%. The latest quarter delivered EPS of -$0.63. The next quarter is forecast at -$2.04. Next year's EPS is expected at $47.98. Instil Bio, Inc. earnings surprise history is a consistent trend of beating forecasts. The quarter that ended August 13, 2026, missed forecasts by 80.0%. The prior quarter beat by 0.0%. Over the last six quarters, Apple has recorded several small beats. These include 88.37% in August 13, 2025.

Instil Bio, Inc. (NASDAQ:TIL) closed at $7.09 USD, losing -$0.12 (-1.66%) from the previous close of $7.21. The stock is currently mid-range between its 52-week high and low $5.67 and $21.98. With a market capitalization of about $48.08 million, Instil Bio, Inc. is classified as a micro-cap and shows higher-than-market volatility (beta ~1.92). Key stats such as the average daily volume over the past year has been around 11.16 thousand shares, trading with heavier-than-usual volume. Headquartered in Dallas, TX, Instil Bio, Inc. operates in the Healthcare sector and the Biotechnology industry. Led by CEO Bronson Crouch, the company employs approximately 17 people and listed since March 19, 2021. Instil Bio, Inc., a biopharmaceutical company, focuses on identifying and advancing therapeutic opportunities.

Instil Bio, Inc. last paid a dividend of 0 per share, Dividend and splits history remains an important factor for investors monitoring long-term returns. A discounted cash flow model estimates fair value at around $1.00. This means the shares are trading above this model’s fair value.

Our AI price prediction model suggests that Instil Bio, Inc. stock has strong potential for upside but may face short-term weakness followed by gains in the medium and long term. 2-Week Outlook: Projected decline of -5.64%, with price expected at $6.69 by October 02, 2026, within a range of $6.55 to $6.83 3-Month Outlook: Projected fall of -30.75%, reaching $4.91 by December 17, 2026, with a range of $3.63 to $5.67. 1-Year Outlook: Projected gain of 69.53%, with price at $12.02 by September 17, 2027, within a range of $0.00 to $10.73.

Instil Bio, Inc. (NASDAQ:TIL) shares are down -35.64% year-to-date currently trading near 52-week highs band. Short-term momentum has been negative over the last quarter, despite recent volatility. Valuation shows Instil Bio, Inc. trading at a premium to the broader market with a P/E of -1.59. Analyst sentiment is bullish, with the majority of ratings in Buy territory and a mean price target of $62.46, suggesting 780.96% upside. Our AI forecast model points to short-term weakness (-5.64% over two weeks), a medium-term fall (-30.75% over three months), and a longer-term gain (69.53% over one year), with expected trading ranges indicating moderate volatility.

Instil Bio, Inc. trades at a P/E ratio of -1.59, slightly below the S&P 500 average, with a price-to-sales ratio of 0.0 and a price-to-book ratio of 0.45 suggesting the stock is closer to book value. The P/FCF stands at -2.04, also below market averages.